Vitamin D analog EB1089 inhibits aromatase expression by dissociation of comodulator WSTF from the CYP19A1 promoter-a new regulatory pathway for aromatase

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1833, Issue 1, 2013, Pages 40-47

  Lundqvist, Johan ^a   Hansen, Susanne Kofoed ^a   Lykkesfeldt, Anne E ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

Aromatase; Breast cancer; CYP19 regulation; Selective aromatase modulator; Vitamin D

Indexed keywords

ANASTROZOLE; AROMATASE; EXEMESTANE; LETROZOLE; SEOCALCITOL; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR; VITAMIN D RECEPTOR INTERACTING REPRESSOR; WILLIAMS SYNDROME TRANSCRIPTION FACTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CELL GROWTH; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AROMATASE; AROMATASE INHIBITORS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CALCITRIOL; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE REGULATORY NETWORKS; HUMANS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; RECEPTORS, CALCITRIOL; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; VITAMIN D;

EID: 84868592918     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2012.10.012     Document Type: Article

References (48)

1. Mazziotti G., Canalis E., Giustina A. Drug-induced osteoporosis: mechanisms and clinical implications. Am. J. Med. 2010, 123:877-884.
2. Czajka-Oraniec I., Simpson E.R. Aromatase research and its clinical significance. Endokrynol. Pol. 2010, 61:126-134.
3. Bulun S.E., Simpson E.R. Aromatase expression in women's cancers. Adv. Exp. Med. Biol. 2008, 630:112-132.
4. Simpson E.R. Aromatase: biologic relevance of tissue-specific expression. Semin. Reprod. Med. 2004, 22:11-23.
5. Simpson E.R., Clyne C., Rubin G., Boon W.C., Robertson K., Britt K., Speed C., Jones M. Aromatase - a brief overview. Annu. Rev. Physiol. 2002, 64:93-127.
6. Simpson E.R., Dowsett M. Aromatase and its inhibitors: significance for breast cancer therapy. Recent Prog. Horm. Res. 2002, 57:317-338.
7. Bulun S.E., Lin Z., Zhao H., Lu M., Amin S., Reierstad S., Chen D. Regulation of aromatase expression in breast cancer tissue. Ann. N. Y. Acad. Sci. 2009, 1155:121-131.
8. 3 exerts tissue-specific effects on estrogen and androgen metabolism Biochimica et Biophysica Acta (BBA). Mol. Cel. Biol. Lipids 2011, 1811:263-270.
9. Krishnan A.V., Swami S., Peng L., Wang J., Moreno J., Feldman D. Tissue-selective regulation of aromatase expression by calcitriol: implications for breast cancer therapy. Endocrinology 2010, 151:32-42.
10. Barrera D., Avila E., Hernández G., Halhali A., Biruete B., Larrea F., Díaz L. Estradiol and progesterone synthesis in human placenta is stimulated by calcitriol. J. Steroid Biochem. Mol. Biol. 2007, 103:529-532.
11. Sun T., Zhao Y., Mangelsdorf D.J., Simpson E.R. Characterization of a region upstream of exon I.1 of the human CYP19 (aromatase) gene that mediates regulation by retinoids in human choriocarcinoma cells. Endocrinology 1998, 139:1684-1691.
12. 3, dexamethasone and progesterone in prostate cancer cells. J. Steroid Biochem. Mol. Biol. 2005, 94:151-157.
13. 3 enhances the enzymatic activity and expression of the messenger ribonucleic acid for aromatase cytochrome P450 synergistically with dexamethasone depending on the vitamin D receptor level in cultured human osteoblasts. Endocrinology 1996, 137:1860-1869.
14. Kinuta K., Tanaka H., Moriwake T., Aya K., Kato S., Seino Y. Vitamin D is an important factor in estrogen biosynthesis of both female and male gonads. Endocrinology 2000, 141:1317-1324.
15. Larsen S.S., Heiberg I., Lykkesfeldt A.E. Anti-oestrogen resistant human breast cancer cell lines are more sensitive towards treatment with the vitamin D analogue EB1089 than parent MCF-7 cells. Br. J. Cancer 2001, 84:686-690.
16. Christensen G.L., Jepsen J.S., Fog C.K., Christensen I.J., Lykkesfeldt A.E. Sequential versus combined treatment of human breast cancer cells with antiestrogens and the vitamin D analogue EB1089 and evaluation of predictive markers for vitamin D treatment. Breast Cancer Res. Treat. 2004, 85:53-63.
17. Colston K.W., Mackay A.G., James S.Y., Binderup L., Chander S., Coombes R.C. EB1089: a new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro. Biochem. Pharmacol. 1992, 44:2273-2280.
18. James S.Y., Mercer E., Brady M., Binderup L., Colston K.W. EB1089, a synthetic analogue of vitamin D, induces apoptosis in breast cancer cells in vivo and in vitro. Br. J. Pharmacol. 1998, 125:953-962.
19. James S.Y., Mackay A.G., Colston K.W. Effects of 1,25 dihydroxyvitamin D3 and its analogues on induction of apoptosis in breast cancer cells. J. Steroid Biochem. Mol. Biol. 1996, 58:395-401.
20. El Abdaimi K., Dion N., Papavasiliou V., Cardinal P.E., Binderup L., Goltzman D., Ste-Marie L.G., Kremer R. The vitamin D analogue EB 1089 prevents skeletal metastasis and prolongs survival time in nude mice transplanted with human breast cancer cells. Cancer Res. 2000, 60:4412-4418.
21. El Abdaimi K., Papavasiliou V., Goltzman D., Kremer R. Expression and regulation of parathyroid hormone-related peptide in normal and malignant melanocytes. Am. J. Physiol. Cell Physiol. 2000, 279:C1230-C1238.
22. Hansen C.M., Hamberg K.J., Binderup E., Binderup L. Seocalcitol (EB 1089): a vitamin D analogue of anti-cancer potential. Background, design, synthesis, pre-clinical and clinical evaluation. Curr. Pharm. Des. 2000, 6:803-828.
23. VanWeelden K., Flanagan L., Binderup L., Tenniswood M., Welsh J. Apoptotic regression of MCF-7 xenografts in nude mice treated with the vitamin D3 analog, EB1089. Endocrinology 1998, 139:2102-2110.
24. Ghous Z., Akhter J., Pourgholami M.H., Morris D.L. Inhibition of hepatocellular cancer by EB1089: in vitro and in vive study. Anticancer Res. 2008, 28:3757-3761.
25. Dalhoff K., Dancey J., Astrup L., Skovsgaard T., Hamberg K.J., Lofts F.J., Rosmorduc O., Erlinger S., Bach Hansen J., Steward W.P., Skov T., Burcharth F., Evans T.R.J. A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma. Br. J. Cancer 2003, 89:252.
26. Evans T.R., Colston K.W., Lofts F.J., Cunningham D., Anthoney D.A., Gogas H., de Bono J.S., Hamberg K.J., Skov T., Mansi J.L. A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer. Br. J. Cancer 2002, 86:680-685.
27. Gulliford T., English J., Colston K.W., Menday P., Moller S., Coombes R.C. A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer. Br. J. Cancer 1998, 78:6-13.
28. Díaz-Cruz E.S., Shapiro C.L., Brueggemeier R.W. Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells. J. Clin. Endocrinol. Metab. 2005, 90:2563-2570.
29. Sonne-Hansen K., Lykkesfeldt A.E. Endogenous aromatization of testosterone results in growth stimulation of the human MCF-7 breast cancer cell line. J. Steroid Biochem. Mol. Biol. 2005, 93:25-34.
30. Lundqvist J., Wikvall K., Norlin M. Vitamin D-mediated regulation of CYP21A2 transcription - A novel mechanism for vitamin D action. Biochim. Biophys. Acta Gen. Subj. 2012, 1820:1553-1559.
31. Murayama A., Kim M., Yanagisawa J., Takeyama K., Kato S. Transrepression by a liganded nuclear receptor via a bHLH activator through co-regulator switching. EMBO J. 2004, 23:1598-1608.
32. 3-induced transrepression by vitamin D receptor through E-box-type elements in the human parathyroid hormone gene promoter. Mol. Endocrinol. 2007, 21:334-342.
33. 3. Endocrinol. Metab. Clin. North Am. 2010, 39:255-269.
34. Meyer M.B., Goetsch P.D., Pike J.W. Genome-wide analysis of the VDR/RXR cistrome in osteoblast cells provides new mechanistic insight into the actions of the vitamin D hormone. J. Steroid Biochem. Mol. Biol. 2010, 121:136-141.
35. Zella L.A., Kim S., Shevde N.K., Pike J.W. Enhancers located in the vitamin D receptor gene mediate transcriptional autoregulation by 1,25-dihydroxyvitamin D3. J. Steroid Biochem. Mol. Biol. 2007, 103:435-439.
36. 3-induced DNA methylation suppresses the human CYP27B1 gene. Mol. Cell. Endocrinol. 2007, 265-266:168-173.
37. Lu X., Meng X., Morris C.A., Keating M.T. A novel human gene, WSTF, is deleted in Williams syndrome. Genomics 1998, 54:241-249.
38. Pike J.W., Meyer M.B. The vitamin D receptor: new paradigms for the regulation of gene expression by 1,25-dihydroxyvitamin D3. Rheum. Dis. Clin. North Am. 2012, 38:13-27.
39. Carlberg C., Seuter S., Heikkinen S. The first genome-wide view of vitamin D receptor locations and their mechanistic implications. Anticancer Res. 2012, 32:271-282.
40. Heikkinen S., Vaisanen S., Pehkonen P., Seuter S., Benes V., Carlberg C. Nuclear hormone 1alpha,25-dihydroxyvitamin D3 elicits a genome-wide shift in the locations of VDR chromatin occupancy. Nucleic Acids Res. 2011, 39:9181-9193.
41. Meyer M.B., Goetsch P.D., Pike J.W. A downstream intergenic cluster of regulatory enhancers contributes to the induction of CYP24A1 expression by 1alpha,25-dihydroxyvitamin D3. J. Biol. Chem. 2010, 285:15599-15610.
42. Ramagopalan S., Heger A., Berlanga A., Maugeri N., Lincoln M., Burrell A., Handunnetthi L., Handel A., Disanto G., Orton S., Watson C., Morahan J., Giovannoni G., Ponting C., Ebers G., Knight J. A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. Genome Res. 2010, 20:1352-1360.
43. Jones G. Vitamin D analogs. Endocrinol. Metab. Clin. North Am. 2010, 39:447-472. (table of contents).
44. Hansen C.M., Binderup L., Hamberg K.J., Carlberg C. Vitamin D and cancer: effects of 1,25(OH)2D3 and its analogs on growth control and tumorigenesis. Front. Biosci. 2001, 6:D820-D848.
45. Hoyer-Hansen M., Bastholm L., Mathiasen I.S., Elling F., Jaattela M. Vitamin D analog EB1089 triggers dramatic lysosomal changes and Beclin 1-mediated autophagic cell death. Cell Death Differ. 2005, 12:1297-1309.
46. Hoyer-Hansen M., Nordbrandt S.P., Jaattela M. Autophagy as a basis for the health-promoting effects of vitamin D. Trends Mol. Med. 2010, 16:295-302.
47. Mathiasen I.S., Lademann U., Jaattela M. Apoptosis induced by vitamin D compounds in breast cancer cells is inhibited by Bcl-2 but does not involve known caspases or p53. Cancer Res. 1999, 59:4848-4856.
48. Evans T.R., Rowlands M.G., Sahota S.S., Coombes R.C. Lack of inhibition of placental estrone sulfatase and aromatase enzymes by vitamin D3 and its analogs. J. Steroid Biochem. Mol. Biol. 1994, 48:563-566.